Farallon Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-6,000
| Closed | -$230K | – | 160 |
|
|
2024
Q2 | $230K | Hold |
6,000
| – | – | ﹤0.01% | 122 |
|
|
2024
Q1 | $353K | Hold |
6,000
| – | – | ﹤0.01% | 125 |
|
|
2023
Q4 | $359K | Sell |
6,000
-188,053
| -97% | -$11.3M | ﹤0.01% | 115 |
|
|
2023
Q3 | $7.38M | Buy |
194,053
+154,000
| +384% | +$5.86M | 0.03% | 91 |
|
|
2023
Q2 | $3.65M | Sell |
40,053
-277,500
| -87% | -$25.3M | 0.02% | 109 |
|
|
2023
Q1 | $20.9M | Sell |
317,553
-132,847
| -29% | -$8.76M | 0.11% | 80 |
|
|
2022
Q4 | $23.3M | Sell |
450,400
-27,600
| -6% | -$1.43M | 0.14% | 77 |
|
|
2022
Q3 | $32.6M | Buy |
+478,000
| New | +$32.6M | 0.18% | 81 |
|
|
2021
Q3 | – | Sell |
-1,550,000
| Closed | -$98M | – | 299 |
|
|
2021
Q2 | $98M | Sell |
1,550,000
-625,000
| -29% | -$39.5M | 0.4% | 53 |
|
|
2021
Q1 | $93.3M | Sell |
2,175,000
-100,000
| -4% | -$4.29M | 0.46% | 50 |
|
|
2020
Q4 | $130M | Hold |
2,275,000
| – | – | 0.78% | 41 |
|
|
2020
Q3 | $68.6M | Buy |
2,275,000
+25,000
| +1% | +$754K | 0.47% | 53 |
|
|
2020
Q2 | $73.5M | Buy |
2,250,000
+250,000
| +13% | +$8.17M | 0.59% | 46 |
|
|
2020
Q1 | $53.6M | Buy |
2,000,000
+1,500,000
| +300% | +$40.2M | 0.46% | 41 |
|
|
2019
Q4 | $15.3M | Buy |
+500,000
| New | +$15.3M | 0.1% | 89 |
|